Skip to content

Dulaglutide (Trulicity) clinical trials: 81 trials

Page 2 of 2

  1. A Study of IBI362 in Chinese Patients With Type 2 Diabetes

    NCT04965506 · Phase 2 · Completed

    Linked paper with results

  2. Glucagon-Like Peptide 1 Receptor Agonist in Diabetes Mellitus Management in Children and Adolescents With Transfusion-Dependent Thalassemia

    NCT07370922 · Phase 2 · Completed

    Linked paper with results

  3. Effects of GLP-1 Analogues on Fluid Intake in Patients With Primary Polydipsia (The GOLD-Study)

    NCT02770885 · Phase 2 · Completed

    Linked paper with results

  4. Therapeutic Strategies for Microvascular Dysfunction in Type 1 Diabetes

    NCT05478707 · Phase 2 · Recruiting

    Linked paper with results

  5. Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM

    NCT04466904 · Phase 1/2 · Completed

    Linked paper with results

  6. Effects of Glucagon Like Peptide 1 (GLP-1) Analogues on Fluid Intake

    NCT03141632 · Phase 2 · Completed

    Linked paper with results

  7. A Study of Tirzepatide (LY3298176) in Healthy Participants and Participants With Type 2 Diabetes (T2DM)

    NCT02759107 · Phase 1 · Completed

    Posted results

  8. A Study of Dulaglutide in Chinese Participants

    NCT01667900 · Phase 1 · Completed

    Posted results

  9. A Study of LY3493269 in Participants With Type 2 Diabetes

    NCT04515576 · Phase 1 · Completed

    Posted results

  10. A Study of the Effect of LY2189265 on Two Blood Pressure Drugs

    NCT01324388 · Phase 1 · Completed

    Posted results

  11. A Study to Compare the Effect of Giving Dulaglutide Using an Auto-injector Versus a Manual Syringe

    NCT01524770 · Phase 1 · Completed

    Posted results

  12. A Study to Evaluate the Effect of LY2189265 on the Speed at Which Food and Drink Leaves the Stomach in Patients With Type 2 Diabetes Mellitus

    NCT01215968 · Phase 1 · Completed

    Posted results

  13. Effect of LY2189265 on Insulin Secretion in Response to Intravenous Glucose

    NCT01300260 · Phase 1 · Completed

    Posted results

  14. A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.

    NCT01301092 · Phase 1 · Completed

    Posted results

  15. A Study of LY2189265 and Sitagliptin in Participants With Type 2 Diabetes

    NCT01408888 · Phase 1 · Completed

    Posted results

  16. A Study of the Effect of Dulaglutide on the Action of Warfarin in Healthy Participants

    NCT01432938 · Phase 1 · Completed

    Posted results

  17. A Study of Dulaglutide in Healthy Participants

    NCT03363906 · Phase 1 · Completed

    Posted results

  18. LY2189265 and Atorvastatin Interaction Study

    NCT01250834 · Phase 1 · Completed

    Posted results

  19. A Single Dose Study of LY2189265 in Subjects With Varying Degrees of Hepatic (Liver) Impairment

    NCT01253304 · Phase 1 · Completed

    Posted results

  20. A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants

    NCT01436201 · Phase 1 · Completed

    Posted results

  21. A Study of the Effect of Dulaglutide on How the Body Handles Oral Contraceptive in Healthy Female Participants

    NCT01458210 · Phase 1 · Completed

    Posted results

  22. A Study of LY3437943 in Participants With Type 2 Diabetes Mellitus (T2DM)

    NCT04143802 · Phase 1 · Completed

    Linked paper with results

  23. A Pharmacokinetic Study Comparing the 14028 Injection and TRULICITY® in Healthy Chinese Subjects

    NCT05459285 · Phase 1 · Completed

    Linked paper with results

  24. Stepping-down Approach in Patients With Chronic Poorly-controlled Diabetes on Advanced Insulin Therapy?

    NCT02846233 · Not applicable · Completed

    Posted results

  25. Comparative Effectiveness of Tirzepatide and Semaglutide in Individuals at Cardiovascular Risk

    NCT07096063 · Phase not stated · Completed

    Linked paper with results

  26. Comparative Study of Tirzepatide Versus Dulaglutide (SURPASS CVOT) or Semaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes

    NCT06779929 · Phase not stated · Completed

    Linked paper with results

  27. Prediction of the SURPASS-CVOT Cardiovascular Outcome Trial in Healthcare Claims Data

    NCT07088718 · Phase not stated · Completed

    Linked paper with results

  28. Renoprotective Effects of Dulaglutide in Patients With Type 2 Diabetic Nephropathy

    NCT06182891 · Not applicable · Completed

    Linked paper with results

  29. Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1RA in CKD

    NCT07309094 · Phase not stated · Recruiting

    Linked paper with results

  30. The Effect of Combined Dulaglutide and Dapagliflozin Treatment vs DPP-4 Inhibitors in Endothelial and Vascular Function in Patients With Type 2 Diabetes Mellitus and Albuminuria

    NCT06611904 · Not applicable · Status unknown

    Linked paper with results

  31. Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

    NCT03590626 · Not applicable · Completed

    Linked paper with results

How PepBank reports evidence